The Mount Sinai Health System will partner with Emergent BioSolutions and ImmunoTek Bio Centers on the development and evaluation of a COVID-19 hyperimmune globulin product, it was announced yesterday. The COVID-HIG is prepared using convalescent plasma from COVID-19 patients to potentially prevent and treat the disease in the absence of a vaccine. The collaboration, which leverages $34.6 million in funding from the Department of Defense, includes a post-exposure prophylaxis study on health care providers at high risk of COVID-19 infection and other high-risk populations.

Related News Articles

Headline
The Food and Drug Administration will host a webinar Aug. 18 at 12 p.m. ET on its umbrella emergency use authorization for certain disposable, single use…
Headline
Almost 80 free-standing children’s hospitals will receive $1.4 billion in relief funds from the Coronavirus Aid, Relief, and Economic Security Act and the…
Headline
The Federal Emergency Management Agency Aug. 10 issued a temporary final rule allocating certain health and medical resources exclusively for domestic use…
Perspective
During the very short time he had left at the end of the Civil War, President Lincoln was already planning ahead…strategizing ways to heal the country and…
Headline
AdventHealth’s Central Florida division is weathering massive financial losses due to the COVID-19 public health emergency, with losses close to $263 million…
Headline
U.S. adults were more likely this June than a year ago to report adverse mental health conditions, substance use and suicidal ideation, according to a report…